BR112022009290A2 - Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70 - Google Patents
Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70Info
- Publication number
- BR112022009290A2 BR112022009290A2 BR112022009290A BR112022009290A BR112022009290A2 BR 112022009290 A2 BR112022009290 A2 BR 112022009290A2 BR 112022009290 A BR112022009290 A BR 112022009290A BR 112022009290 A BR112022009290 A BR 112022009290A BR 112022009290 A2 BR112022009290 A2 BR 112022009290A2
- Authority
- BR
- Brazil
- Prior art keywords
- genetically modified
- malignities
- therapy
- hematopoietic cell
- cells targeting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001138—Tumor necrosis factors [TNF] or CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4231—Cytokines
- A61K40/4232—Tumor necrosis factors [TNF] or CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934945P | 2019-11-13 | 2019-11-13 | |
| US202063034510P | 2020-06-04 | 2020-06-04 | |
| PCT/IB2020/060718 WO2021095009A1 (en) | 2019-11-13 | 2020-11-13 | Therapy for hematopoietic cell malignancies using genetically engineered t cells targeting cd70 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022009290A2 true BR112022009290A2 (pt) | 2022-08-09 |
Family
ID=73554470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022009290A BR112022009290A2 (pt) | 2019-11-13 | 2020-11-13 | Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220387571A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4058051A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023501590A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220100912A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114845730A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020384951A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022009290A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3158090A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292467A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022005815A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021095009A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| MX2022015586A (es) | 2020-06-12 | 2023-03-15 | Nkarta Inc | Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70. |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| US20220387488A1 (en) * | 2021-05-12 | 2022-12-08 | Crispr Therapeutics Ag | Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies |
| US20230128917A1 (en) * | 2021-09-14 | 2023-04-27 | Crispr Therapeutics Ag | Genetically engineered immune cells having a disrupted cd83 gene |
| CN117173092B (zh) * | 2023-06-28 | 2024-04-09 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 一种基于图像处理的鼻咽癌放疗方法及系统 |
| WO2025193386A1 (en) | 2024-03-13 | 2025-09-18 | Caribou Biosciences, Inc. | Treatment regimens for autoimmune disease with cd19-targeting engineered immune cells |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11466291B2 (en) * | 2016-07-06 | 2022-10-11 | Cellectis | Sequential gene editing in primary immune cells |
| BR112019023608A2 (pt) * | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | Materiais e métodos para células manipuladas e seus usos em imuno-oncologia |
| MX2020008184A (es) * | 2018-02-01 | 2020-09-22 | Pfizer | Receptores de antigeno quimericos dirigidos a cd70. |
| US20200063100A1 (en) * | 2018-05-11 | 2020-02-27 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
-
2020
- 2020-11-13 BR BR112022009290A patent/BR112022009290A2/pt not_active Application Discontinuation
- 2020-11-13 JP JP2022527744A patent/JP2023501590A/ja active Pending
- 2020-11-13 EP EP20812137.6A patent/EP4058051A1/en not_active Withdrawn
- 2020-11-13 US US17/776,846 patent/US20220387571A1/en not_active Abandoned
- 2020-11-13 CN CN202080086735.4A patent/CN114845730A/zh active Pending
- 2020-11-13 KR KR1020227019519A patent/KR20220100912A/ko not_active Withdrawn
- 2020-11-13 IL IL292467A patent/IL292467A/en unknown
- 2020-11-13 WO PCT/IB2020/060718 patent/WO2021095009A1/en not_active Ceased
- 2020-11-13 MX MX2022005815A patent/MX2022005815A/es unknown
- 2020-11-13 CA CA3158090A patent/CA3158090A1/en active Pending
- 2020-11-13 AU AU2020384951A patent/AU2020384951A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022005815A (es) | 2022-08-10 |
| CA3158090A1 (en) | 2021-05-20 |
| KR20220100912A (ko) | 2022-07-18 |
| EP4058051A1 (en) | 2022-09-21 |
| US20220387571A1 (en) | 2022-12-08 |
| IL292467A (en) | 2022-06-01 |
| WO2021095009A1 (en) | 2021-05-20 |
| CN114845730A (zh) | 2022-08-02 |
| AU2020384951A1 (en) | 2022-05-19 |
| AU2020384951A9 (en) | 2023-06-29 |
| JP2023501590A (ja) | 2023-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022009204A2 (pt) | Terapia de carcinoma de células renais (rcc) usando células t geneticamente manipuladas visando cd70 | |
| BR112021021843A2 (pt) | Composições de proteína de fusão quimicamente projetada e métodos de uso das mesmas | |
| CL2021002249A1 (es) | Composiciones de partículas de sílice mesoporosa para administración viral | |
| CL2019002717A1 (es) | Receptores de unión a antígeno mejorados. | |
| MX2022005815A (es) | Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70. | |
| MX2020012561A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiazepinona e inmunoterapeuticos y metodos de uso de las mismas. | |
| BR112022009141A2 (pt) | Terapia contra tumores sólidos cd70+ usando células t geneticamente manipuladas visando cd70 | |
| BR112021016984A2 (pt) | Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação | |
| BR112014006176A8 (pt) | Rna transcrito in vitro ou rna sintético, composição, método para gerar uma população de células t geneticamente modificadas por rna, e, uso de uma célula t geneticamente modificada | |
| CL2018000270A1 (es) | Constructos de anticuerpo para cd70 y cd3. | |
| BR112018070636A2 (pt) | método de tratamento de um sujeito humano que tem câncer, anticorpo, uso de um anticorpo, anticorpo para uso, combinação de um anticorpo, kit para uso no tratamento de câncer, composição farmacêutica, anticorpo biespecífico, método para tratamento de câncer, anticorpo biespecífico para uso e método de depleção de células t reguladoras em um tumor sólido em um sujeito | |
| CO2019000946A2 (es) | Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos | |
| BR112021021542A2 (pt) | Terapia celular alogênica de malignidades de células b com o uso de células t geneticamente modificadas que têm como alvo cd19 | |
| BR112017001183A2 (pt) | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado | |
| BR112018070676A2 (pt) | construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos | |
| MX2022001776A (es) | Terapias de combinacion de inmuno oncologia con conjugados de il-2. | |
| BR112019014986A2 (pt) | anticorpo que alveja bcma e uso do mesmo | |
| MX2017002205A (es) | Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer. | |
| BR112021024978A2 (pt) | Composições engajadoras específicas para macrófagos e métodos de uso das mesmas | |
| CO2017010190A2 (es) | Terapias cd20, terapias cd22 y terapias de combinación con una célula que expresa un receptor quimérico de antígeno (car) de cd19 | |
| EP4643874A3 (en) | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy | |
| BR112019018863A8 (pt) | Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos | |
| MX2017003645A (es) | Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva. | |
| BR112017018770A2 (pt) | redução da tolerância imunológica induzida por pd-l1 | |
| BR112021026382A2 (pt) | Uso de células t de receptor de antígenos quimérico e inibidores de células nk para tratamento de câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |